Immunocore Holdings Ltd (IMCR)
$36.86
$0.54
(1.49%)
As on 01-Sep-2026 16:00EDT
Market cap
$1,886 Mln
Revenue (TTM)
$404 Mln
P/E Ratio
--
P/B Ratio
4.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
111
-
Debt to Equity
0.9
-
Book Value
$--
-
EPS
$-0.2
-
Face value
--
-
Shares outstanding
51,498,617
8 Years Aggregate
CFO
$-434.49 Mln
EBITDA
$-474.15 Mln
Net Profit
$-477.69 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Immunocore Holdings (IMCR)
| 6.2 | 9.0 | 27.6 | 14.4 | -13.2 | 1.3 | -- |
|
BSE Sensex*
| -9.9 | -2.3 | 2.7 | -5.1 | 5.3 | 5.9 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Immunocore Holdings (IMCR)
| 17.7 | -56.5 | 19.7 | 66.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Immunocore Holdings (IMCR)
|
36.9 | 1,885.9 | 403.7 | -9.3 | 3.2 | -2.3 | -- | 4.5 |
| 82.7 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 260.3 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 71.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.9 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 107.7 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 363.8 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 538.7 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 583.2 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 353.4 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Immunocore Holdings (IMCR)
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and... internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom. Read more
-
CEO & Director
Dr. Bahija Jallal Ph.D.
-
CEO & Director
Dr. Bahija Jallal Ph.D.
-
Headquarters
Abingdon
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Immunocore Holdings (IMCR)
What is the current share price of Immunocore Holdings Ltd (IMCR) Today?
The share price of Immunocore Holdings Ltd (IMCR) is $36.86 (NASDAQ) as of 01-Sep-2026 16:00 EDT. Immunocore Holdings Ltd (IMCR) has given a return of -13.15% in the last 3 years.
What is the current PB & PE ratio of Immunocore Holdings Ltd (IMCR)?
Since, TTM earnings of Immunocore Holdings Ltd (IMCR) is negative, P/E ratio is not available.
The P/B ratio of Immunocore Holdings Ltd (IMCR) is 4.51 times as on 28-Aug-2026, a 13 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-66.15 |
4.59 |
2024 |
-36.14 |
4.09 |
2023 |
-76.34 |
9.06 |
2022 |
-61.28 |
7.86 |
2021 |
-11.25 |
6.49 |
What is the 52 Week High and Low of Immunocore Holdings Ltd (IMCR)?
The 52-week high and low of Immunocore Holdings Ltd (IMCR) are Rs 40.71 and Rs 27.56 as of 02-Sep-2026.
What is the market cap of Immunocore Holdings Ltd (IMCR)?
Immunocore Holdings Ltd (IMCR) has a market capitalisation of $ 1,886 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Immunocore Holdings Ltd (IMCR)?
Before investing in Immunocore Holdings Ltd (IMCR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.